Ligand Pharmaceuticals Incorporated
$5.28B- Market cap
- $5.64B
- Debt
- +$374.08M
- Cash
- −$733.52M
Capital structure 94% equity / 6% debt · EV / Revenue 19.70x · EV / EBITDA 32.95x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: LGND stock price near parity vs IBKR $282.97 current versus $254.04 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at IBKR's multiple
Implied fair value · at LGND's multiple
Snapshot Sep 8, 2026, 1:33 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple discount
Premium justified
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: LGND FY 2025 (ended Dec 31, 2025) · IBKR FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 94% equity / 6% debt · EV / Revenue 19.70x · EV / EBITDA 32.95x
Capital structure 3% equity / 97% debt · EV / Revenue 75.26x · EV / EBITDA 20.38x
IBKR carries the larger enterprise value at $183.64B against $5.28B; LGND trades on the lower EV / Revenue multiple (19.70x vs 75.26x); IBKR on the lower EV / EBITDA (20.38x vs 32.95x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
LIGAND PHARMACEUTICALS INCORPORATED · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
INTERACTIVE BROKERS GROUP, INC. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.37x
34.07x
Net debt / EBITDA
Leverage against operating earnings
-2.24x
19.72x
Cash and equivalents
Liquid reserves on the balance sheet
$733.52M
$4.96B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
$374.08M
$182.72B
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.